Morningstar Investment Services LLC Has $1.34 Million Holdings in Pfizer Inc. (NYSE:PFE)

Morningstar Investment Services LLC decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 53.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,792 shares of the biopharmaceutical company's stock after selling 61,101 shares during the quarter. Morningstar Investment Services LLC's holdings in Pfizer were worth $1,338,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC increased its position in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. Madison Investment Advisors LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $5,360,000. Teacher Retirement System of Texas increased its position in Pfizer by 93.3% during the fourth quarter. Teacher Retirement System of Texas now owns 1,969,261 shares of the biopharmaceutical company's stock worth $52,244,000 after buying an additional 950,358 shares during the last quarter. Finally, Northwest & Ethical Investments L.P. increased its position in Pfizer by 0.6% during the fourth quarter. Northwest & Ethical Investments L.P. now owns 265,072 shares of the biopharmaceutical company's stock worth $7,032,000 after buying an additional 1,541 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Shares of PFE stock traded down $0.03 during trading on Monday, hitting $24.45. The company had a trading volume of 18,537,531 shares, compared to its average volume of 41,870,152. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a market capitalization of $138.98 billion, a P/E ratio of 17.74, a price-to-earnings-growth ratio of 0.89 and a beta of 0.58. The stock's 50-day moving average price is $24.07 and its 200 day moving average price is $24.71. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.82 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.04%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is presently 124.64%.

Analyst Ratings Changes

PFE has been the topic of a number of recent analyst reports. Citigroup boosted their price target on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Morgan Stanley boosted their price target on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. TD Cowen lowered their price target on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. Finally, HSBC lowered their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.